18889881171
Kalkine 0
countryflagUS

Alector Inc

Healthcare US ALEC

1.55USD
0.04(2.65%)

Last update at 2025-06-17T16:57:00Z

Day Range

1.491.62
LowHigh

52 Week Range

2.008.90
LowHigh

Fundamentals

  • Previous Close 1.51
  • Market Cap226.22M
  • Volume238574
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-177.39400M
  • Revenue TTM61.51M
  • Revenue Per Share TTM0.66
  • Gross Profit TTM -76.80100M
  • Diluted EPS TTM-1.71

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -130.05600M -36.32900M -190.22800M -105.38500M -52.24800M
Minority interest - - - - -
Net income -133.31000M -28.01400M -182.96300M -99.81100M -52.24800M
Selling general administrative 61.03M 55.04M 59.40M 35.09M 11.93M
Selling and marketing expenses - - - - -
Gross profit 133.62M 207.09M 21.10M 21.22M 27.68M
Reconciled depreciation 8.47M 8.31M 7.26M 5.57M 1.02M
Ebit -146.30600M -45.67500M -202.43900M -119.97800M -58.30700M
Ebitda -137.83400M -37.36000M -195.17400M -114.40400M -57.28800M
Depreciation and amortization 8.47M 8.31M 7.26M 5.57M 1.02M
Non operating income net other - 1.03M 4.95M 9.02M -
Operating income -137.83400M -37.36000M -195.17400M -114.40400M -57.28800M
Other operating expenses 271.45M 244.44M 216.27M 135.62M 84.97M
Interest expense -16.25000M 8.31M 0.00000M 0.00000M 0.00000M
Tax provision 3.25M - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 3.25M -8.31500M -7.26500M -5.57400M 5.04M
Total revenue 133.62M 207.09M 21.10M 21.22M 27.68M
Total operating expenses 271.45M 244.44M 216.27M 135.62M 84.97M
Cost of revenue - - - - 73.03M
Total other income expense net 7.78M 1.03M 4.95M 9.02M 5.04M
Discontinued operations - - - - -
Net income from continuing ops -133.31000M -36.32900M -190.22800M -105.38500M -52.24800M
Net income applicable to common shares -133.31000M -36.32900M -190.22800M -105.38500M -52.24800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 621.83M 787.65M 814.66M 488.25M 421.91M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 16.95M 11.00M 7.07M 8.20M 4.36M
Total liab 487.67M 573.21M 513.93M 220.72M 227.17M
Total stockholder equity 134.16M 214.44M 300.72M 267.53M 194.74M
Deferred long term liab - - - - 0.60M
Other current liab 82.74M -14.90100M -55.12900M 9.80M -5.20300M
Common stock 0.00800M 0.00800M 0.00800M 0.00800M 0.00700M
Capital stock 0.00800M 0.00800M 0.00800M 0.00800M 0.00700M
Retained earnings -710.07800M -579.68700M -446.37700M -410.04800M -219.82000M
Other liab - 444.13M 334.57M 108.89M 123.73M
Good will - - - - -
Other assets - 7.88M 7.05M 4.09M 2.15M
Cash 74.56M 154.32M 329.15M 49.97M 89.64M
Cash and equivalents - - - - -
Total current liabilities 177.95M 45.58M 48.22M 44.20M 31.80M
Current deferred revenue 82.97M 48.23M 90.80M 23.89M 30.16M
Net debt -35.63700M -110.99600M -281.55100M 1.29M -41.60500M
Short term debt 8.46M 8.06M 7.79M 7.51M 6.57M
Short long term debt - - - - -
Short long term debt total 38.92M 43.33M 47.60M 51.26M 48.04M
Other stockholder equity 844.04M 798.70M 748.04M 676.96M -7.49900M
Property plant equipment - 53.33M 27.33M 30.18M 62.33M
Total current assets 565.81M 726.43M 749.71M 421.51M 357.44M
Long term investments - - - - -
Net tangible assets - 214.44M 300.72M 267.53M 194.74M
Short term investments 474.31M 558.53M 406.10M 363.34M 263.43M
Net receivables - 2.59M 7.39M - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 3.77M 4.19M 4.75M 3.00M 0.28M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.18M -4.57500M -0.94300M 0.61M 0.14M
Additional paid in capital - - - - -
Common stock total equity - - 0.00800M 0.00800M 0.00700M
Preferred stock total equity - - - - -
Retained earnings total equity - - -446.37700M -410.04800M -219.82000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 7.42M 7.88M 7.05M 4.09M 2.15M
Deferred long term asset charges - - - - -
Non current assets total 56.02M 61.21M 64.94M 66.74M 64.48M
Capital lease obligations 38.92M 43.33M 47.60M 51.26M 48.04M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -159.01400M -46.41600M -100.01900M -33.60900M -224.11900M
Change to liabilities 65.81M 1.60M 2.39M 0.55M 171.68M
Total cashflows from investing activities -159.01400M -49.66300M -105.05100M -48.87400M -224.11900M
Net borrowings - - - - -
Total cash from financing activities 4.51M 30.30M 232.11M 172.35M 131.15M
Change to operating activities -6.28500M -11.15100M 3.47M 8.79M 2.68M
Net income -133.31000M -36.32900M -190.22800M -105.38500M -52.24800M
Change in cash -174.82900M 279.18M -39.67200M 24.17M 34.49M
Begin period cash flow 330.62M 51.44M 91.11M 66.94M 32.45M
End period cash flow 155.79M 330.62M 51.44M 91.11M 66.94M
Total cash from operating activities -20.32900M 298.55M -166.73400M -99.30800M 127.46M
Issuance of capital stock 0.00000M 0.00000M 224.60M 170.13M 133.05M
Depreciation 8.47M 8.31M 7.26M 5.57M 1.02M
Other cashflows from investing activities - - - -33.60900M -222.23500M
Dividends paid - - - - -
Change to inventory - - - - 2.45M
Change to account receivables - - - - 0.24M
Sale purchase of stock - 30.30M 7.51M 2.32M -1.90400M
Other cashflows from financing activities 1.46M 30.30M 7.51M 2.23M -224.11900M
Change to netincome 44.98M 40.78M 30.63M 16.32M 4.33M
Capital expenditures 4.12M 3.25M 5.03M 15.27M 1.88M
Change receivables - - - - -
Cash flows other operating - 284.06M -15.97700M -9.86600M -
Exchange rate changes - - - - -
Cash and cash equivalents changes - 279.18M -39.67200M 24.17M -
Change in working capital 59.53M 283.68M -15.22200M -12.27400M 174.36M
Stock based compensation 46.15M 40.78M 30.52M 16.28M 6.92M
Other non cash items -1.16300M 2.10M 0.93M -3.50400M -2.59400M
Free cash flow -24.44600M 295.30M -171.76600M -114.57300M 125.58M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ALEC
Alector Inc		 0.04 2.65% 1.55 - 526.32 3.68 1.78 2.38 -8.3996
NVO
Novo Nordisk A/S		 -2.38 3.09% 74.64 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.16 4.04% 75.15 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.28 0.51% 448.63 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -3.845 0.74% 518.84 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Alector Inc

131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Dr. Tillman Ulf Gerngross Ph.D. Co-Founder & Chairman 1964
Dr. Arnon Rosenthal Ph.D. Co-Founder, CEO & Director 1956
Dr. Sara Kenkare-Mitra Ph.D. Pres and Head of R&D 1968
Mr. Calvin Yu VP of Fin. 1976
Dr. Marc Grasso M.D. Chief Financial Officer 1974
Mr. Peter Heutink Ph.D. Chief Scientific Officer NA
Michelle Corral VP of Communications & Investor Relations NA
Ms. Danielle Pasqualone J.D., Ph.D. Gen. Counsel NA
Erica Jefferson VP of Communications & Public Affairs NA
Ms. Clare Hunt M.B.A. Chief People Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.